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Abstract
Aim/hypothesis To assess whether low-dose glucocorticoid
treatment induces adverse metabolic effects, as is evident
for high glucocorticoid doses.
Methods In a randomised placebo-controlled double-blind
(participants and the investigators who performed the
studies and assessed the outcomes were blinded) dose–
response intervention study, 32 healthy men (age 22±
3 years; BMI 22.4±1.7 kg/m2) were allocated to prednis-
olone 7.5 mg once daily (n=12), prednisolone 30 mg once
daily (n=12), or placebo (n=8) for 2 weeks using block
randomisation. Main outcome measures were glucose, lipid
and protein metabolism, measured by stable isotopes,
before and at 2 weeks of treatment, in the fasted state and
during a two-step hyperinsulinaemic clamp conducted in
the Clinical Research Unit of the Academic Medical
Centre, Amsterdam, the Netherlands
Results Prednisolone, compared with placebo, dose depen-
dently and significantly increased fasting plasma glucose
levels, whereas only prednisolone 30 mg increased fasting
insulin levels (29±15 pmol/l). Prednisolone 7.5 mg and
prednisolone 30 mg decreased the ability of insulin to suppress
endogenous glucose production (by 17±6% and 46±7%,
respectively, vs placebo). Peripheral glucose uptake was not
reduced by prednisolone 7.5 mg, but was decreased by
prednisolone 30 mg by 34±6% (p<0.0001). Compared with
placebo, prednisolone treatment tended to decrease lipolysis
in the fasted state (p=0.062), but both prednisolone 7.5 mg
and prednisolone 30 mg decreased insulin-mediated suppres-
sion of lipolysis by 11±5% and 34±6%, respectively. Finally,
prednisolone treatment increased whole-body proteolysis
during hyperinsulinaemia, which tended to be driven by
prednisolone 30 mg (5±2%; p=0.06). No side effects were
reported by the study participants. All participants completed
the study and were analysed.
Conclusions/interpretation Not only at high doses but also
at low doses, glucocorticoid therapy impaired intermediary
metabolism by interfering with the metabolic actions of
insulin on liver and adipose tissue. These data indicate that
even low-dose glucocorticoids may impair glucose toler-
ance when administered chronically.
Trial registration: ISRCTN83991850
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Abbreviations
DEXA Dual emission X-ray absorptiometry
EGP Endogenous glucose production
FPG Fasting plasma glucose
GC Glucocorticoid
LBM Lean body mass
Rd Rate of disappearance
REE Resting energy expenditure
SAT Subcutaneous adipose tissue
VAT Visceral adipose tissue
Introduction
Glucocorticoids (GCs) are the cornerstone in the treatment
of numerous chronic autoimmune and inflammatory dis-
eases, including rheumatoid arthritis [1], polymyalgia
rheumatica [2] and giant cell arteritis [3], systemic lupus
erythematosus [4] and inflammatory bowel diseases [5].
GC treatment is accompanied by significant metabolic
adverse effects, including insulin resistance, glucose intol-
erance and diabetes, visceral adiposity, dyslipidaemia and
skeletal muscle atrophy [6]. The development of these
adverse metabolic effects is dependent on the administered
dose [7], and has mainly been studied with high doses. As
such, daily administration of 36 mg prednisolone equivalent
impaired glucose tolerance by reducing hepatic [8] and
peripheral insulin sensitivity [9]. Furthermore, 30 mg
prednisolone daily stimulated adipose tissue, but not
whole-body, lipolysis [10], and induced dyslipidaemia
[11]. In addition, 60 mg prednisolone daily was shown to
stimulate breakdown of skeletal muscle tissue [12]. Finally,
chronic exposure to markedly increased endogenous GC
levels, as shown in patients with Cushing’s syndrome,
unfavourably affected body fat distribution by promoting
visceral fat accumulation and hepatic steatosis [13].
However, most patients treated with GCs for prolonged
time periods receive, following an induction dose, GC
dosages in the lower range: ≤7.5 mg prednisolone equiv-
alent daily. Although the efficacy of these doses on disease
activity in various conditions is well established [1–4, 7],
the extent to which these low dosages induce adverse
metabolic effects is unclear. In large retrospective case–
control studies, it was demonstrated that low-dose GC
treatment increased the odds for the initiation of blood-
glucose lowering therapy by 63% [14] and increased the
risk of developing diabetes [15]. In contrast, in clinical
trials with chronic use of low-dose GC treatment, incident
diabetes is reported less frequently [16]. The main
limitation of these data is that no distinction can be made
between disease-induced and age-related abnormalities on
the one hand, and the metabolic abnormalities induced by
low-dose prednisolone treatment on the other. To date, no
studies have assessed the effects of low-dose GC treatment
on the three most important pathways of intermediary
metabolism. In addition, previous studies addressing the
metabolic adverse effects of GC treatment have only
studied the (hyper)acute effects and typically administered
a single dose.
Thus, in the present study, we studied the effects of
2 week low-dose prednisolone treatment (7.5 mg daily) on
glucose, lipid and protein metabolism using stable isotopes
in healthy men, and included a typical induction dosage of
prednisolone (i.e. 30 mg daily), which is known to impair
intermediary metabolism, and a matching placebo treat-
ment. Through combined infusion of tracers for glucose
and protein metabolism, as well as lipolysis, we assessed
differences in the sensitivity of metabolic fluxes to the
dose-dependent effects of GC treatment.
Methods
Participants Thirty-two healthy white men were recruited
via local advertisements. All participants were in good
health as confirmed by medical history, physical examina-
tion, screening blood tests and a 75 g 2 h OGTT, performed
at screening visit. Inclusion criteria included: age 18–
35 years; BMI 20–25 kg/m2; and normoglycaemia as
defined by fasting plasma glucose (FPG)<5.6 mmol/l and
2 h glucose<7.8 mmol/l during OGTT. Exclusion criteria
were the presence of any disease, use of any medication,
first-degree relative with type 2 diabetes, smoking, shift
work, a history of GC use, excessive sport activities (i.e.
more often than twice/week) and changes in weight in the
3 months prior to study participation. The study was
approved by an independent ethics committee and the
study was conducted in accordance with the Declaration of
Helsinki. All participants provided written informed con-
sent before participation.
Study design The study was a randomised double-blind
placebo-controlled dose-response intervention study. Fol-
lowing assessment of eligibility and baseline measure-
ments, participants were randomised to receive either
prednisolone 7.5 mg once daily (n=12), prednisolone
30 mg once daily (n=12), or placebo (n=8) treatment for
a period of 14 days using block randomisation, as carried
out by the department of experimental pharmacology of the
VU University Medical Centre. On day −2 and day 13 of
treatment, body composition, body fat distribution and liver
fat content were quantified. On day −1 and on day 14 of
treatment, glucose kinetics, lipolysis and proteolysis were
measured in the basal state and during a two-step hyper-
insulinaemic–euglycaemic clamp using stable isotopes
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(electronic supplementary material [ESM] Fig. 1a, b). All
measurements were conducted following a 12 h overnight
fast with the individuals in the semi-supine position.
Participants refrained from drinking alcohol for a period
of 24 h before the study days and did not perform strenuous
exercise for a period of 48 h before the study days. During
all visits, including a follow-up visit at day 7 of treatment,
safety and tolerability were assessed. A patient flow
diagram is shown in ESM Fig. 2.
Assessment of body composition/body fat distribution Body
composition was measured by dual energy X-ray absorpti-
ometry (DEXA) scans (Delphi A; Hologic, Waltham, MA,
USA). Magnetic resonance imaging (MRI), for determina-
tion of visceral adipose tissue (VAT) and subcutaneous
adipose tissue (SAT) area at the level of L3-L4, and proton
magnetic resonance spectroscopy (1H-MRS), to quantify
liver fat content, were performed using a 1.5 T MRI
scanner (Sonata; Siemens, Erlangen, Germany), as de-
scribed previously by Tushuizen et al. [17, 18]. All
magnetic resonance examinations (DVR) and quantification
of abdominal fat compartments (MHM) were done by a
single experienced investigator.
Clamp After an overnight fast of 12 h, participants were
admitted to the Clinical Research Unit at 07:30 hours. An
indwelling cannula was inserted into an antecubital vein for
infusion of stable-isotope tracers, glucose and insulin. To
obtain arterialised venous blood samples, a retrograde
cannula was inserted in a contralateral wrist vein and
maintained in a thermoregulated box at 50°C. To keep the
sampling line patent 0.9% NaCl was infused. [6,6-2H2]
Glucose, [1,1,2,3,3-2H5]glycerol and L-[1-
13C]valine were
used as tracers (>99% enriched; Cambridge Isotopes,
Andover, MA, USA) to study glucose kinetics, lipolysis
and valine turnover respectively. At t=0 h (08:00 hours),
blood samples were drawn for determination of background
enrichments. Then, a primed continuous infusion of
isotopes was started: [6,6-2H2]glucose (prime: 11 μmol/
kg; continuous: 0.11 μmol kg−1min−1), [1,1,2,3,3-2H5]
glycerol (prime: 1.6 μmol/kg; continuous: 0.11 μmol
kg-1 min-1), and L-[1-13C]valine (prime: 13.7 μmol/kg;
continuous: 0.153 μmol kg−1 min−1) and continued until
the end of the clamp. After a 2 h equilibrium period (14 h
of fasting), three blood samples were drawn for determina-
tion of basal glucose concentrations, isotope enrichment,
and levels of glucoregulatory hormones and NEFA.
Thereafter, a two-step hyperinsulinaemic–euglycaemic
clamp was started: step 1 included an infusion of insulin
at a rate of 20 mU m−2 min−1 (Actrapid 100 U/ml; Novo
Nordisk, Alphen aan den Rijn, the Netherlands) to assess
hepatic insulin sensitivity. Glucose 20% was started to
maintain a plasma glucose concentration of 5 mmol/l.
[6,6-2H2]Glucose was added to the glucose solution to
achieve glucose enrichments of 1% in order to approximate
the values for enrichment reached in plasma and thereby
minimising changes in isotopic enrichment due to changes
in the infusion rate of exogenous glucose. Plasma glucose
concentrations were measured every 5 min at bedside. After
2 h of insulin infusion, five blood samples were drawn at
5 min intervals for the measurement of glucose concen-
trations and isotopic enrichments. Another blood sample
was drawn for measurement of glucoregulatory hormones
and NEFA. Hereafter, insulin infusion was increased to a
rate of 60 mU m−2 min−1 (step 2) to assess peripheral
insulin sensitivity. After 2 h of insulin infusion, blood
sampling for glucose, isotope enrichments, glucoregulatory
hormones and NEFA was repeated (ESM Fig. 1b).
Indirect calorimetry Oxygen consumption (

VO2) and car-
bon dioxide production (

VO2) were measured continuously
during the final 20 min of both the basal state and during
step 2 of the hyperinsulinaemic–euglycaemic clamp by
indirect calorimetry using a ventilated hood system (Vmax
model 2900; Sensormedics, Anaheim, CA, USA). The

VO2
and

VO2 measurements during the last 10 min were used
for further calculations.
Study medication Prednisolone tablets were purchased
from Pfizer (Sollentuna, Sweden) and matching placebo
tablets were obtained from Xendo Drug Development
(Groningen, the Netherlands). The tablets were encapsulat-
ed in order to allow the treatment to be blinded, as
described previously [19]. Study medication was taken at
08:00 hours during the 2 week treatment except on days 13
and 14, when it was ingested at 06:00 hours. Patients kept a
diary in which the exact time of medication intake during
the study was registered.
Glucose, lipid, and valine measurements Plasma glucose
concentrations were measured with the glucose oxidase
method using a Biosen C-line Plus glucose analyser (EKF
Diagnostics, Barleben/Magdeburg, Germany). Plasma
NEFA concentrations were measured with an enzymatic
colorimetric method (NEFA-C test kit; Wako Chemicals,
Neuss, Germany) with an intra-assay variation of 1%, inter-
assay variation of 4–15% and a detection limit of
0.02 mmol/l. [6,6-2H2]Glucose, [1,1,2,3,3,-
2H5]glycerol
and L-[1-13C]valine enrichment were measured with gas
chromatography–mass spectrometry as described previously
[20–22]. Briefly, temperature-programmed gas chromatogra-
phy with split injection (Model 6890; Agilent Technologies,
Palo Alto, USA) was coupled to a mass selective detector
(model 5973 Agilent Technologies) in the electron impact
ionisation mode for glucose and valine analysis and in the
positive chemical ionisation mode for glycerol. Exact gas
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chromatography and mass spectometry variables are given in
Ackermans et al., Ackermans et al. and Geukers et al. [20–22].
Glucoregulatory hormones Insulin was determined on an
Immulite 2000 system (Diagnostic Products, Los Angeles,
CA, USA) with a chemiluminescent immunometric assay,
intra-assay variation of 3–6%, an inter-assay variation of 4–6%
and a detection limit of 15 pmol/l. Glucagon was determined
with the Linco 125I radioimmunoassay (St Charles, MO,
USA) with an intra-assay variation of 9–10%, an inter-assay
variation of 5–7% and a detection limit of 15 ng/l.
Calculations Endogenous glucose production (EGP) and
the peripheral uptake of glucose (rate of disappearance, Rd)
were calculated using modified versions of the Steele
equations for the non-steady state and were expressed as
μmol kg−1 min−1 as described previously [23, 24].
Lipolysis (glycerol turnover) and proteolysis (valine turn-
over) were computed using formulae for steady state
kinetics adapted for stable isotopes [20, 22] and were
expressed as μmol kg−1 min−1. The equations are provided
in ESM Fig. 3. The abbreviated Weir equation was used to
calculate the 24 h energy expenditure. Glucose oxidation
and fatty acid oxidation rates were derived from oxygen
consumption and carbon oxide production as reported
previously [25]. Glucose oxidation during insulin infusion
was additionally expressed as percentage of glucose Rd.
Statistics Data are presented as mean values±SD, or as
median (interquartile range) in case of skewed distribution.
Absolute changes from baseline (on treatment value−pre-
treatment value) were compared between the groups using
the Kruskal–Wallis test. Non-parametric analysis was
chosen because of the relatively small number of partic-
ipants and the uneven group sizes. Only in the case of a
significant finding were prednisolone 7.5 mg and prednis-
olone 30 mg compared against placebo by post hoc testing,
using the Mann–Whitney U test. To correct for multiple
testing, Bonferroni correction was applied by multiplying
the obtained p value from the Mann–Whitney U test by the
numbers of comparisons (i.e. two) that were carried out. All
statistical analyses were run on SPSS for Windows version
15.0 (SPSS, Chicago, IL, USA). A p<0.05 was considered
statistically significant.
Results
Anthropometric characteristics The participant character-
istics at inclusion are presented in Table 1; no differences
were observed among the three treatment groups at
baseline. BMI, lean body mass (LBM) and total fat mass
were not altered by prednisolone treatment irrespective of
the dose (ESM Table 1). Liver fat content averaged 1.3±
0.9% before treatment in all participants and was not
changed by either study medication (ESM Table 1). VAT
and SAT areas averaged 74±19 and 136±38 cm2, respec-
tively, at baseline in all participants, and were not altered by
treatment with either prednisolone dose (ESM Table 1).
Resting energy expenditure Resting energy expenditure
(REE) in the basal state was 100±11 kJ kg−1 day−1 prior
to treatment and was not changed by either prednisolone
dose (Table 2). Insulin infusion increased REE before
treatment to 106±9 kJ kg−1 day−1 (p<0.01), an effect that
was not changed by prednisolone treatment (Table 2).
Glucose metabolism Prednisolone treatment dose depen-
dently and significantly increased FPG, despite fasting
hyperinsulinaemia in the prednisolone 30 mg group
(Table 3). Fasting EGP was only increased by prednisolone
30 mg (Fig. 1a), whereas suppression of EGP by insulin was
Characteristic Placebo Prednisolone p value
7.5 mg 30 mg
n 8 12 12
Age (years) 22±3 22±2 22±3 0.740
Weight (kg) 76.9±8.7 74.8±7.2 77.0±5.4 0.250
Height (cm) 184±5.6 183±7.6 186±4 0.641
BMI (kg/m2) 22.7±2.1 22.2±1.9 22.4±1.2 0.906
LBM (%) 78.6±7.9 82.1±3.9 80.7±2.5 0.731
Fat mass (%) 16.9±4.7 15.9±2.8 14.8±3.5 0.531
Systolic BP (mmHg) 118±11 125±9 127±9 0.172
Diastolic BP (mmHg) 74±14 72±14 79±13 0.392
FPG (mmol/l) 5.1±0.3 5.0±0.2 5.0±0.4 0.899
2 h OGTT (mmol/l) 4.2±0.8 4.7±0.9 4.2±1.1 0.407
Table 1 Participant characteris-
tics at inclusion
Data are mean±SD
Significance was tested by
Kruskal–Wallis. No differences
were observed between the
groups at baseline
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impaired by both prednisolone doses (Fig. 1b). Peripheral
glucose disposal was significantly decreased by prednisolone
30 mg, but not by prednisolone 7.5 mg (Fig. 1c). In the total
study population, at baseline, glucose oxidation in the basal
state was 5.8 (3.1–8.2) μmol kg−1 min−1, which was
significantly increased during treatment with prednisolone
30 mg, but not with prednisolone 7.5 mg (Table 2). Pre-
treatment, glucose oxidation increased to 20.0 (18.3–
23.7)μmol kg−1 min−1 (9±5% of Rd) during hyperinsulinae-
mia (p<0.001 compared with the basal state). Prednisolone
treatment did not affect the absolute levels of glucose
oxidation during hyperinsulinaemia; however, prednisolone
30 mg increased glucose oxidation relative to Rd (Table 2).
Lipid metabolism Lipolysis in the fasted state tended to be
decreased by prednisolone treatment (p=0.062), which was
driven by the prednisolone 30 mg arm (p=0.09) (Fig. 2a).
Insulin-mediated suppression of lipolysis was markedly and
dose dependently impaired by prednisolone during hyper-
insulinaemic conditions (Fig. 2b, c). Similarly to changes in
lipolysis, basal NEFA levels were decreased prednisolone
treatment, which seemed to be driven by prednisolone
30 mg (Table 2). During step 1 of insulin infusion
(20 mU m−2 min−1), insulin-mediated suppression of
plasma NEFA levels was dose dependently decreased by
prednisolone treatment (ESM Table 2). During the second
step of insulin infusion (60 mU m−2 min−1), NEFA levels
were reduced to detection level in the placebo group and
prednisolone 7.5 mg group, but remained detectable in
participants in the prednisolone 30 mg arm (ESM Table 2).
Fasting triacylglycerol (TG) levels were increased by
prednisolone 30 mg only (Table 3). In the total study
population, pre-treatment, fasting fatty acid oxidation rate
was 1.5 (1.3–1.8) μmol kg−1 min−1 and decreased during
insulin infusion to 0.4 (0.2–0.7) μmol kg−1 min−1 (p<
0.001). Basal fatty acid oxidation was reduced by prednis-
olone 30 mg treatment, but fatty acid oxidation during
insulin infusion was not affected by any of the treatment
arms (Table 2).
Protein metabolism Prednisolone treatment did not affect
proteolysis in the fasted state (Fig. 3a); however, prednisolone
treatment increased proteolysis under hyperinsulinaemic
conditions (Fig. 3b, c).
Test state Pre-treatment On treatment p valuea p valueb p valuec
Basal REE (kJ kg−1day−1)
Placebo 95 (86–110) 89 (86–98) 0.139 NA NA
7.5 98 (91–107) 99 (92–109)
30 106 (91–114) 107 (98–110)
REE during clamp (kJ kg−1 day−1)
Placebo 102 (95–114) 100 (95–111) 0.352 NA NA
7.5 105 (97–110) 106 (99–111)
30 111 (96–111) 109 (96–111)
Basal glucose oxidation (μmol kg−1 min−1)
Placebo 7.7 (4.9–9.0) 5.5 (4.2–8.0) 0.006 0.430 0.002
7.5 5.8 (3.0–8.5) 5.8 (3.2–12.6)
30 5.1 (3.0–7.7) 11.2 (7.7–14.6)
Glucose oxidation during clamp (μmol kg−1 min−1)
Placebo 20.3 (18.8–22.2) 19.0 (15.8–25.2) 0.133 NA NA
7.5 19.6 (17.5–24.0) 16.1 (11.8–20.1)
30 19.4 (15.5–25.4) 20.0 (17.4–22.8)
Glucose oxidation during clamp (% of Rd)
Placebo 11.4 (7.8–16.1) 9.0 (5.8–15.9) <0.001 0.728 <0.001
7.5 9.4 (4.9–12.0) 9.3 (4.8–13.6)
30 8.5 (4.9–9.8) 25.1 (15.8–41.3)
Basal fatty acid oxidation (μmol kg−1 min−1)
Placebo 1.4 (1.2–1.5) 1.3 (1.2–1.8) 0.02 0.640 0.022
7.5 1.4 (1.2–1.6) 1.6 (1.1–1.7)
30 1.7 (1.5–1.9) 1.1 (1.0–1.5)
Fatty acid oxidation clamp (μmol kg−1 min−1)
Placebo 0.4 (0.1–0.6) 0.5 (0.1–0.7) 0.083 NA NA
7.5 0.5 (0.1–0.7) 0.7 (0.3–1.0)
30 0.5 (0.2–0.8) 0.5 (0.2–0.7)
Table 2 REE and glucose and
fatty acid oxidation in the fasted
state and during insulin infusion
before and during 2 week treat-
ment with placebo, prednisolone
7.5 mg or prednisolone 30 mg
Data are medians (interquartile
range)
Bonferroni correction was applied
to correct for multiple testing
7.5, prednisolone 7.5 mg; 30,
prednisolone 30 mg; NA, not
available
a Between-group changes from
baseline were tested by Kruskal–
Wallis
b Placebo vs prednisolone
7.5 mg or c 30 mg (post hoc
testing by Mann–Whitney U in
the case of a significant finding
with Kruskal–Wallis)
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Glucoregulatory hormones Prednisolone 7.5 mg did not
change fasting plasma insulin levels or glucagon levels.
Prednisolone 30 mg, in contrast, induced both fasting
hyperinsulinaemia and hyperglucagonaemia (Table 3). Be-
fore treatment, insulin levels in the entire study population
during the clamp were 171 (153–183) pmol/l (step 1) and
533 (485–564) pmol/l (step 2). These levels remained
unchanged during the on-treatment clamps, although there
was a tendency towards increased insulin levels in the
placebo group (ESM Table 2). Glucagon levels remained
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Fig. 1 The effects of prednisolone treatment on glucose metabolism.
a Prednisolone treatment increased basal EGP. This was driven by
prednisolone 30 mg once daily. b EGP during insulin infusion was
dose dependently increased by prednisolone treatment. c The rate of
glucose disappearance was decreased by prednisolone 30 mg, but not
by prednisolone 7.5 mg once daily. Data represent means±SEM.
Black bars, before treatment; white bars, day 14 of treatment.
Between-group changes from baseline were tested by Kruskal–Wallis
(indicated by top line). Post hoc tests were done by Mann–Whitney U
with Bonferroni correction for multiple testing (indicated by line with
brackets). **p<0.01; ***p<0.001. PLB, placebo
Table 3 Fasting metabolic variables before and during 2 week treatment with placebo, prednisolone 7.5 mg or prednisolone 30 mg
Variable Pre-treatment On treatment p valuea p valueb p valuec
FPG (mmol/l)
Placebo 5.0±0.2 4.8±0.3 <0.0001 0.06 <0.001
7.5 4.9±0.2 5.1±0.3
30 4.7±0.2 5.4±0.3
Fasting plasma insulin (pmol/l)
Placebo 30 (16–51) 28 (<15–38) 0.0004 1.0 0.002
7.5 29 (<15–40) 19 (<15–42)
30 19 (<15–27) 34 (23–51)
Fasting glucagon (ng/l)
Placebo 49 (39–55) 41 (39–48) 0.019 1.0 0.05
7.5 65 (53–74) 61 (53–74)
30 48 (41–59) 62 (53–80)
Fasting NEFA (nmol/l)
Placebo 0.5±0.2 0.5±0.1 0.017 1.0 0.11
7.5 0.4±0.1 0.5±0.1
30 0.6±0.2 0.4±0.1
Fasting TG (mmol/l)
Placebo 0.54 (0.41–0.88) 0.53 (0.34–0.73) 0.019 0.836 0.028
7.5 0.76 (0.55–1.00) 0.74 (0.62–0.91)
30 0.59 (0.35–0.72) 0.68 (0.62–1.20)
Data are means ± SD or medians (interquartile range)
For plasma insulin levels, the limit of quantification was
15 pmol/l; in the statistical calculations, a value of 7.5 pmol/l was chosen for values below this limit
7.5, prednisolone 7.5 mg; 30, prednisolone 30 mg
a Between-group changes from baseline were tested by Kruskal–Wallis
b Placebo vs prednisolone 7.5 mg or c 30 mg (post hoc testing by Mann–Whitney U in the case of a significant finding with Kruskal–Wallis;
Bonferroni correction was applied to correct for multiple testing)
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increased during step 1, but not step 2, of the hyper-
insulinaemic clamp during prednisolone 30 mg treatment
(ESM Table 2).
Safety and tolerability One participant in the prednisolone
30 mg group complained of gastric discomfort which was
mild of nature and did not require any intervention.
Otherwise, no treatment-related side effects were reported
in either group.
Discussion
Low-dose GC treatment is chronically prescribed to a great
number of patients, but to date it is uncertain whether low-
dose GC treatment induces adverse metabolic effects, as is
evident for higher GC doses. The present study is the first
to demonstrate that low-dose GC therapy, that is, just above
the normal daily cortisol replacement dose for adrenal
insufficiency, significantly impairs the effects of insulin on
glucose and lipid metabolism, but not on whole-body
protein metabolism. Using a relatively long exposure time,
i.e. 2 weeks, we report that treatment with prednisolone
7.5 mg impaired the ability of insulin to suppress EGP,
whole-body lipolysis and plasma NEFA levels. These
effects were present after only 2 weeks of treatment and
occurred in the absence of changes in body weight, LBM,
liver fat content and body fat distribution. Our data,
demonstrating clear low-dose prednisolone-induced hepatic
and adipose tissue insulin resistance, provide supportive
mechanisms for observations made in large retrospective
case–control studies that reported increased risk to develop
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Fig. 3 The effect of prednisolone treatment on valine appearance (Ra). a
Valine turnover in the basal state was not affected by prednisolone
treatment. b Overall, valine turnover was increased during step 1 of the
hyperinsulinaemic–euglycaemic clamp by prednisolone treatment. This
seemed driven by prednisolone 30 mg in post hoc analysis, but failed to
reach statistical significance. c A similar pattern was observed during
step 2 of the clamp, where overall prednisolone treatment increased
valine turnover; however, in post hoc testing, no significance was
reached for either dose compared with placebo. Data represent means±
SEM. Black bars, before treatment; white bars, day 14 of treatment.
Between-group changes from baseline were tested by Kruskal–Wallis
(indicated by top line). Post hoc tests were done by Mann–Whitney U
with Bonferroni correction for multiple testing (indicated by line with
brackets). *p<0.05; †p=0.06. PLB, placebo
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Fig. 2 The effects of prednisolone treatment on glycerol appearance
(Ra). a Prednisolone treatment tended to decrease basal lipolysis,
which seemed caused by the prednisolone 30 mg once daily dose. b
During insulin infusion targeted at 200 pmol/l, prednisolone treatment
dose dependently increased glycerol turnover. This reached signifi-
cance for prednisolone 30 mg, but remained a trend for prednisolone
7.5 mg once daily. c At higher insulin (600 pmol/l) during step 2 of
the clamp, a similar pattern was observed, with a dose-dependent
increase of whole-body lipolysis with prednisolone treatment. Data
represent means±SEM. Black bars, before treatment; white bars,
day 14 of treatment. Between-group changes from baseline were
tested by Kruskal–Wallis (indicated by top line). Post hoc tests were
done by Mann–Whitney U with Bonferroni correction for multiple
testing (indicated by line with brackets). *p<0.05; **p<0.01; †p=
0.062; ‡p=0.09. PLB, placebo
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diabetes [15] and increased need to initiate blood-glucose
lowering therapy [14] during or following low-dose GC
therapy.
In prospective studies, the reported incidence of diabetes
at lower GC doses has been more modest, although there
was considerable variation depending on the patient group
exposed [16]. The numbers reported in these clinical trials
may underestimate the actual incidence of diabetes.
Although not well specified in the different studies, most
studies relied on fasting glucose measurements to monitor
changes in glucose tolerance. Our data demonstrate a very
mild increase in fasting glucose and unchanged fasting
insulin levels, but show evident changes induced by
prednisolone 7.5 mg in metabolic fluxes under insulin-
stimulated conditions. This observation is in line with
previous studies reporting large postprandial glucose
excursions with only modest changes in fasting glucose
levels [19, 26]. These data imply that, in order to properly
assess the effects of GCs on glucose metabolism, measure-
ments under stimulated conditions should be performed,
such as an OGTT or a glucose day curve.
By including an additional treatment arm, we were able
to study the dose-dependent effects of prednisolone
treatment. Prednisolone 30 mg, an induction dosage often
used in the clinic for short-term treatment, impaired the
effects of insulin on EGP, glucose disposal and lipolysis to
a greater extent than prednisolone 7.5 mg. In addition,
prednisolone 30 mg increased proteolysis under hyper-
insulinaemic conditions, increased glucagon levels and
augmented fasting TG levels. Surprisingly, prednisolone
30 mg increased both basal glucose oxidation (absolute
levels) and glucose oxidation during the clamp (expressed
as % of Rd). Increased basal glucose oxidation has, to our
knowledge, not been reported previously following GC
treatment. We hypothesise that prednisolone treatment
induced metabolic inflexibility. This phenomenon refers to
the inability to adjust fuel oxidation to substrate availability.
As such, impaired fat oxidation in the fasted state was
extensively shown in obese insulin-resistant and type 2
diabetic individuals [27]. In addition, following high-dose
prednisolone treatment, FPG levels were, albeit it margin-
ally, increased, which could have contributed to augmented
glucose oxidation in the basal state. The finding that GC
treatment increased glucose oxidation under hyperinsuli-
naemic conditions has been reported previously in non-
diabetic individuals who were exposed to dexamethasone
treatment [28]. GCs are well known to impair the insulin-
stimulated glycogen synthesis pathway [29] and, therefore,
increased glucose oxidation was proposed to serve as a
mechanism to compensate for reduced glycogen synthesis
in the presence of higher glucose levels within the skeletal
muscle [28]. Our data similarly indicate preferential glucose
oxidation compared with glycogen synthesis pathways, as
absolute glucose oxidation rates were not altered despite
lower glucose uptake. Glucose oxidation as a percentage of
Rd was thus increased. Finally, prednisolone 30 mg tended
to decrease basal lipolysis and NEFA levels compared with
placebo. In acute studies, cortisol infusion was shown to
increase lipolysis in the fasted state. In these studies,
hyperinsulinaemia was prevented by performing a pancre-
atic clamp with insulin infusion at basal levels [30, 31]. In
studies addressing the effects of chronic GC treatment,
typically no changes were observed in whole-body lipolysis
in the fasted state [32], and fasting insulin levels were
increased [33, 34]. In our study we found a tendency
towards decreased lipolysis. As lipolysis is more sensitive
to small changes in insulin concentration than EGP [35,
36], and plasma NEFA levels are closely correlated with
changes in lipolysis, we hypothesise that decreased basal
lipolysis and NEFA levels in individuals receiving
prednisolone 30 mg may be because of the observed
prednisolone-induced 80% increase in fasting plasma
insulin levels. The negative correlation between the
treatment-induced change in fasting plasma insulin and
fasting NEFA levels (r=−0.564; p=0.001) supports our
hypothesis. Another hypothesis is that prednisolone 30 mg
decreased the sympathetic tone to adipose tissue, resulting
in lower rates of basal lipolysis [37].
The mechanisms underlying prednisolone-induced insulin
resistance on the various metabolic fluxes have not been
elucidated. GCs were shown to interfere with insulin signalling
in vitro and in vivo in rodents in liver [38], adipose tissue [39]
and skeletal muscle [40]. On the other hand, GCs may also
directly activate genes involved in the regulation of various
metabolic fluxes. As such, GCs were shown to induce
phosphoenolpyruvate carboxykinase, the rate-controlling
enzyme in hepatic glucose production [41]. In addition,
hormone-sensitive lipase, a major regulator of adipose tissue
lipolysis was demonstrated to be regulated by GCs [42].
Moreover, GCs directly activated muscle ring finger-1 and
atrogin-1, proteins involved in skeletal muscle proteolysis
[43]. Finally, GCs impaired glucose transport into skeletal
muscle independent of changes in insulin signalling [6].
In the present study we exposed healthy volunteers to
different doses of prednisolone, allowing us to specifically
measure the metabolic effects of prednisolone. In clinical
practice, prednisolone is used to treat patients with chronic
inflammatory diseases. As systemic inflammation also
impairs insulin sensitivity [44], the effects of GCs on various
fluxes, given their combined anti-inflammatory and meta-
bolic effects, could be more complex in this population.
One potential, yet inevitable, limitation of our experimental
design when addressing the effects of real-life oral predniso-
lone treatment, as compared with previously reported, more
artificial cortisol infusion studies, is that our clamp tests were
performed under non-steady-state prednisolone levels. As
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prednisolone has a t1/2 of 4–6 h, the final part of the clamp
may have been performed under lower prednisolone levels.
However, plasma prednisolone levels may be a poor marker
of its dynamics, as many actions of prednisolone are genomic
of nature, which take a number of hours to become effected.
In addition, our participants were treated for 2 weeks, in
contrast to the acute studies that have been mostly conducted
up to now and, therefore, differences caused by the acute
effects of prednisolone treatment may be very limited.
We conclude that GC treatment, even at a low so-called
maintenance dose that is prescribed to large numbers of
patients for prolonged periods of time, impairs both glucose
metabolism and lipolysis by impairing the metabolic actions of
insulin on the liver and adipose tissue. The results of this study
uncover the mechanisms by which GC doses just above
cortisol replacement levels, particularly when used chronically,
may impair glucose tolerance in susceptible patients. Physi-
cians treating patients with low-dose GCs should be aware of
the induction of metabolic disturbances and should not solely
rely on fasting measurements. In addition, our study indicates
that insulin-sensitising therapies could be considered when
treating patients with GC therapy. As such, the thiazolidine-
dione troglitazone was shown to prevent GC-induced glucose
intolerance in healthy humans [45]. Troglitazone, however, is
no longer available for use in humans, and therefore a search
for other options to alleviate GC-induced insulin resistance
seems justified. In this regard, the current development of the
so-called dissociated GC receptor agonists, which aim to
separate the anti-inflammatory and dysmetabolic effects of
GCs, may be very interesting [46].
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